Induction of Clinical Response Using Rifaximin in Crohn's Disease

NCT00603616 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Placebo Comparator
DRUG: Rifaximin

Sponsor

Scott Lee

Collaborators

[object Object]